Search results
Results from the WOW.Com Content Network
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast ...
Lilly also raised its 2024 profit forecast and said sales of Zepbound crossed $1 billion for the first time in a quarter since its launch in late 2023. ... Increased manufacturing capacity for Eli ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity ...
Eli Lilly on Tuesday forecast 2024 profit above Wall Street estimates on soaring demand for Zepbound, its recently approved weight-loss drug, and said it would have new supply from expanded ...
Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6. As per data from Benzinga Pro, the Wall Street estimates sales of $13 ...
Eli Lilly reported fourth quarter and full-year earnings for 2024 on Thursday. The results largely beat Wall Street estimates and sent the stock up about 2%. But the company missed on GLP-1 sales.
But on Thursday, Eli Lilly blew past Wall Street estimates for its GLP-1 sales. It beat Wall Street quarterly sales projections by 13% — with total sales of $4.3 billion for weight-loss drug ...